Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

AM Capital confident of alpha in next 36 months as fund gains 12% through April

Tuesday, May 20, 2014

Komfie Manalo, Opalesque Asia:

Chicago-based hedge fund manager AM Capital Advisors is confident its fund can generate alpha in the next 36 months. AM Advisors President Aaron Miller made the statement as the long/short U.S. equity fund generated 12% gains through April (+3.89% month-to-date) versus the DOW index +0.05%, (+0.74% MTD), NASDAQ -1.09% (-2.49% MTD), and the S&P 500 index at +2.06% (+0.53%. MTD).

He said in an interview, "We’re not bearish, we just think its going to be difficult with for big advances because [Janet] Yellen would put the brakes on by raising rates. If one were to have this opinion, we feel concentrated positions with a realistic catalyst combined with selling derivatives is a good strategy for a market that might not appreciate significantly anytime soon. We feel this provides the best risk reward by essentially locating companies that are trading at a significant discount to their peers and overall market and shorting companies that are trading at overvalued multiplies compared to their peers and the market."

Since inception in July 2009, the hedge fund returned 137.99% versus the DOW index 96.28%, NASDAQ 122.87%, and the S&P 500 index at 104.59% during the same period.

Miller explained that decent stock selection, selling derivatives wisely, and re-allocating positions once the risk reward changes due to price movements, were all factors that affected the fund’s perform......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for